Cover Image

Markers of bone remodeling in metastatic bone disease

Many cancers have a strong propensity to spread to bone. The processes involved in cancer dissemination to bone are complex and variable, and the changes in bone metabolism, once bony metastases have occurred, are usually profound. This review surveys the usefulness of bone markers in the diagnosis...

Full description

Saved in:
Bibliographic Details
Main Authors: Fohr, Berthold (Author) , Dunstan, Colin R. (Author) , Seibel, Markus J. (Author)
Format: Article (Journal)
Language:English
Published: 01 November 2003
In: The journal of clinical endocrinology & metabolism
Year: 2003, Volume: 88, Issue: 11, Pages: 5059-5075
ISSN:1945-7197
DOI:10.1210/jc.2003-030910
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1210/jc.2003-030910
Get full text
Author Notes:Berthold Fohr, Colin R. Dunstan, and Markus J. Seibel

MARC

LEADER 00000caa a2200000 c 4500
001 1808704754
003 DE-627
005 20230426090947.0
007 cr uuu---uuuuu
008 220630s2003 xx |||||o 00| ||eng c
024 7 |a 10.1210/jc.2003-030910  |2 doi 
035 |a (DE-627)1808704754 
035 |a (DE-599)KXP1808704754 
035 |a (OCoLC)1341463279 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Fohr, Berthold  |d 1967-  |e VerfasserIn  |0 (DE-588)115759816  |0 (DE-627)691570434  |0 (DE-576)290061067  |4 aut 
245 1 0 |a Markers of bone remodeling in metastatic bone disease  |c Berthold Fohr, Colin R. Dunstan, and Markus J. Seibel 
264 1 |c 01 November 2003 
300 |a 17 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 30.06.2022 
520 |a Many cancers have a strong propensity to spread to bone. The processes involved in cancer dissemination to bone are complex and variable, and the changes in bone metabolism, once bony metastases have occurred, are usually profound. This review surveys the usefulness of bone markers in the diagnosis and follow-up of patients with malignant bone disease.In patients with established bone metastases, most markers of bone remodeling are abnormal compared with healthy controls or cancer patients without bone lesions. Although bone markers may have a potential as diagnostic tools in cancer patients, the available data do not allow final conclusions regarding the accuracy and validity of any of the presently used markers in the diagnosis of bone metastases.As regards monitoring of anticancer therapy, most markers of bone remodeling respond to active treatments. These indices therefore may have the potential to be used in the monitoring of antitumor therapies. However, most if not all of the available evidence on the use of bone markers in monitoring anticancer therapy is observational, and it remains unclear whether they have any beneficial effects on overall outcome. The same is true for their prognostic value, although evidence suggests that suppressed levels of bone formation or high rates of bone resorption are independent predictors of poor survival. 
700 1 |a Dunstan, Colin R.  |e VerfasserIn  |0 (DE-588)1261486331  |0 (DE-627)1808705289  |4 aut 
700 1 |a Seibel, Markus J.  |e VerfasserIn  |0 (DE-588)115432884  |0 (DE-627)691315086  |0 (DE-576)175045410  |4 aut 
773 0 8 |i Enthalten in  |t The journal of clinical endocrinology & metabolism  |d Oxford : Oxford University Press, 1941  |g 88(2003), 11, Seite 5059-5075  |h Online-Ressource  |w (DE-627)323606261  |w (DE-600)2026217-6  |w (DE-576)094425523  |x 1945-7197  |7 nnas  |a Markers of bone remodeling in metastatic bone disease 
773 1 8 |g volume:88  |g year:2003  |g number:11  |g pages:5059-5075  |g extent:17  |a Markers of bone remodeling in metastatic bone disease 
856 4 0 |u https://doi.org/10.1210/jc.2003-030910  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20220630 
993 |a Article 
994 |a 2003 
998 |g 115759816  |a Fohr, Berthold  |m 115759816:Fohr, Berthold  |d 910000  |d 910100  |e 910000PF115759816  |e 910100PF115759816  |k 0/910000/  |k 1/910000/910100/  |p 1  |x j 
999 |a KXP-PPN1808704754  |e 4159515428 
BIB |a Y 
SER |a journal 
JSO |a {"recId":"1808704754","language":["eng"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"note":["Gesehen am 30.06.2022"],"person":[{"given":"Berthold","family":"Fohr","role":"aut","roleDisplay":"VerfasserIn","display":"Fohr, Berthold"},{"roleDisplay":"VerfasserIn","display":"Dunstan, Colin R.","role":"aut","family":"Dunstan","given":"Colin R."},{"given":"Markus J.","family":"Seibel","role":"aut","roleDisplay":"VerfasserIn","display":"Seibel, Markus J."}],"title":[{"title":"Markers of bone remodeling in metastatic bone disease","title_sort":"Markers of bone remodeling in metastatic bone disease"}],"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"id":{"eki":["323606261"],"zdb":["2026217-6"],"issn":["1945-7197"]},"origin":[{"publisherPlace":"Oxford ; Bethesda, Md.","dateIssuedDisp":"1941-","dateIssuedKey":"1941","publisher":"Oxford University Press ; Endocrine Society"}],"name":{"displayForm":["Endocrine Society"]},"part":{"text":"88(2003), 11, Seite 5059-5075","volume":"88","extent":"17","year":"2003","pages":"5059-5075","issue":"11"},"titleAlt":[{"title":"JCEM"},{"title":"The Journal of clinical endocrinology"}],"pubHistory":["1.1941 -"],"recId":"323606261","language":["eng"],"corporate":[{"roleDisplay":"Herausgebendes Organ","display":"Endocrine Society","role":"isb"}],"disp":"Markers of bone remodeling in metastatic bone diseaseThe journal of clinical endocrinology & metabolism","type":{"media":"Online-Ressource","bibl":"periodical"},"note":["Gesehen am 30.03.2017"],"title":[{"title_sort":"journal of clinical endocrinology & metabolism","title":"The journal of clinical endocrinology & metabolism","subtitle":"JCEM"}]}],"physDesc":[{"extent":"17 S."}],"name":{"displayForm":["Berthold Fohr, Colin R. Dunstan, and Markus J. Seibel"]},"id":{"doi":["10.1210/jc.2003-030910"],"eki":["1808704754"]},"origin":[{"dateIssuedDisp":"01 November 2003","dateIssuedKey":"2003"}]} 
SRT |a FOHRBERTHOMARKERSOFB0120 

Similar Items